Behavioral screening for neuroactive drugs in zebrafish by Rihel, J & Schier, AF
This is the pre-peer reviewed version of the following article: Rihel J and Schier AF (2012).  Behavioral 
screening for neuroactive drugs in zebrafish.  Developmental Neurobiology, 72(3):373-385., which has 
been published in final form at http://onlinelibrary.wiley.com/doi/10.1002/dneu.20910/full 
 
Behavioral Screening for Neuroactive Drugs in Zebrafish 
Jason Rihel1 and Alexander F. Schier1,2,3,4 
1Department of Molecular and Cellular Biology, 2Division of Sleep Medicine, 3Center for 
Brain Science, 4Harvard Stem Cell Institute; Harvard University, Cambridge, MA 02138, 
USA 
e-mail: schier@fas.harvard.edu, rihel@fas.harvard.edu 
Tel: 617.496.4835 Fax: 617.495.9300 
Summary 
The larval zebrafish has emerged as a vertebrate model system amenable to small molecule 
screens for probing diverse biological pathways.  Two large-scale small molecule screens 
examined the effects of thousands of drugs on larval zebrafish sleep/wake and photomotor 
response behaviors.  Both screens identified hundreds of molecules that altered zebrafish 
behavior in distinct ways. The behavioral profiles induced by these small molecules enabled the 
clustering of compounds according to shared phenotypes. This approach identified regulators of 
sleep/wake behavior and revealed the biological targets for poorly characterized compounds.  
Behavioral screening for neuroactive small molecules in zebrafish is an attractive complement 
to in vitro screening efforts, because the complex interactions in the vertebrate brain can only be 
revealed in vivo.  
 
The problem of psychotropic drug discovery  
It is estimated that more than 60 million Americans and 450 million people worldwide suffer from 
some form of mental illness, but the search for new drugs to alleviate psychiatric and central 
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nervous system (CNS) disorders is in crisis (Agid et al., 2007; Miller, 2010).  Compared to drugs 
in other therapy categories, the development of CNS drugs costs more (US $849 million per 
compound), and their approval takes longer (an average of 8.8 years) and is more difficult 
(approval rate of 8.2%) (Pangalos et al., 2007; Miller, 2010).  Even more problematic is the 
dearth of innovative ideas to discover new drugs. Many compounds currently in clinical trials 
merely repurpose approved structures for slightly different therapeutic indications.  Other leads 
provide slightly greater efficacy on well-trodden single disease targets with questionable 
therapeutic relevance. The lack of progress is not surprising, considering that tools for high-
throughput in vivo drug discovery and characterization are not available. In vitro screening 
assays have identified compounds with improved binding efficacy on specific targets, but in vitro 
studies do not reliably predict therapeutic outcomes in vivo (Geddes et al., 2000; Fischer-
Barnicol et al., 2008). Indeed, most effective psychoactive compounds were serendipitously 
discovered decades ago in whole-animal behavioral contexts (Wong et al., 2005; Ban, 2006; 
Kokel and Peterson, 2008). 
 
An alternative to in vitro target-based screens is phenotype-based, whole organism 
screening.  Whole organism screens keep intact the complex architecture of the brain’s 
signaling networks.  Equally important, whole-organism screens do not require well-validated 
targets to discover compounds that give desirable phenotypic outcomes. Although the benefit of 
systematic in vivo screens is well recognized, it is cost- and time- prohibitive to implement such 
screens in mammals.  For example, the Squibb anti-tuberculosis screen that discovered 
isoniazid required the phenotyping of more than 5000 compounds in mice (reviewed in (Zon and 
Peterson, 2005; Kokel and Peterson, 2008)).  Recent studies in zebrafish suggest that this 
model organism can be used for the high-throughput behavioral screening for neuroactive 
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molecules and complement in vitro and mammalian systems. 
 
Small Molecule Screening in Zebrafish 
Long recognized for their powerful genetics, the zebrafish has emerged in recent years as a 
cost-effective model system for whole organism small molecule screening.  Several features of 
zebrafish biology that enable genetic studies are also valuable for small molecule screens.  
Zebrafish are cheap to grow in the laboratory.  A single breeding pair can produce hundreds of 
fertilized embryos per week.  These embryos develop rapidly into a free-swimming larva with 
complex behaviors as early as 4 days post-fertilization.  The embryos and larvae are small and 
can easily be transferred into 96-well plates for high-throughput developmental and behavioral 
assays.  Each step of a zebrafish screen can now be fully automated, from loading, orienting, 
imaging, and laser-dissection (Pardo-Martin et al., 2010).  In addition, small molecules can be 
added directly to the water and readily taken up by the fish through the gills or skin.  This 
straightforward delivery of bioactive compounds not only facilitates high-throughput automation 
of assays but also provides exquisite control over experimental timing to avoid developmental 
effects.   
 
Since Peterson and colleague’s proof of principle study on developmental perturbagens 
(Peterson et al., 2000), many small molecule screens have been conducted in zebrafish, 
especially in the context of developmental processes.  Because these screens have recently 
been thoroughly reviewed elsewhere (MacRae and Peterson, 2003; Peterson et al., 2004; Zon 
and Peterson, 2005; Wheeler and Brandli, 2009; Peal et al., 2010; Strahle and Grabher, 2010; 
Taylor et al., 2010), we will only highlight a few important examples here.  In one striking early 
success, a small molecule screen identified two chemical suppressors of the zebrafish gridlock 
mutation (in the transcriptional repressor hey2 gene), which disrupts normal aorta development 
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and leads to a lack of circulation to the trunk and tail (Peterson et al., 2004).  The suppressors 
did not directly affect the gridlock disease gene but instead acted to upregulate vascular 
endothelial growth factor (VEGF), which promotes blood vessel formation.  Thus, not only can 
whole organism screens identify small molecules that can rescue a genetic disease, but they 
can also highlight novel disease-relevant molecular pathways that in vitro assays would likely 
miss.   
 
In another study, a zebrafish small molecule screen identified the prostaglandin pathway as a 
regulator of hematopoietic stem cell (HSC) number in vivo, an effect that is conserved in mice 
and may have clinical applications to enhance HSC number in cord blood transplants (Lord et 
al., 2007; North et al., 2007).  This screen also identified nitric oxide signaling as an important 
regulator of HSC number in zebrafish and revealed the importance of blood flow in promoting 
HSC numbers (North et al., 2009). These experiments demonstrate another power of small 
molecule screens—the parallel nature of chemical screens allows for the simultaneous 
manipulation and study of numerous biological pathways. 
 
Other developmental events that have been investigated by small molecule screens in zebrafish 
include cell cycle regulation (Murphey et al., 2006), FGF signaling (Molina et al., 2009),  BMP 
signaling  (Yu et al., 2008), hair cell death (Owens et al., 2008; Ou et al., 2009), retinal blood 
vessel growth (Kitambi et al., 2009), melanocyte biology (Budi et al., 2008; Hultman et al., 
2008), cancer biology (Yeh et al., 2009), heart rhythms (Peal et al., 2011), dietary lipid 
absorption (Clifton et al., 2010) and tissue and fin regeneration (Mathew et al., 2007; Oppedal 
and Goldsmith, 2010).  Clearly, many biological processes in zebrafish are amenable to high 
throughput small molecule screens.  
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Probing Zebrafish Behavior with Small Molecules 
Recent experiments in both larval and adult zebrafish have tested the behavioral effects of 
psychotropic compounds, including drugs of abuse (Gerlai et al., 2000; Darland and Dowling, 
2001; Bilotta et al., 2002; Dlugos and Rabin, 2003; Lockwood et al., 2004; Gerlai et al., 2006; 
Lau et al., 2006; Gerlai et al., 2008; Kily et al., 2008; Lopez-Patino et al., 2008; Lopez Patino et 
al., 2008; Egan et al., 2009; Fernandes and Gerlai, 2009; Gerlai et al., 2009; MacPhail et al., 
2009; Webb et al., 2009; Blaser et al., 2010; Cachat et al., 2010; Irons et al., 2010; Sackerman 
et al., 2010; Wong et al., 2010; Dlugos et al., 2011; Mathur and Guo, 2011; Maximino et al., 
2011), anxiolytics and anxiogenics (Levin et al., 2007; Bencan and Levin, 2008; Bencan et al., 
2009; Egan et al., 2009; Lau et al., 2011; Maximino et al., 2011), anti-psychotics (Giacomini et 
al., 2006; Boehmler et al., 2007), hallucinogens (Swain et al., 2004; Blank et al., 2009; 
Grossman et al., 2010; Seibt et al., 2010), and sedatives (Zhdanova et al., 2001; Ruuskanen et 
al., 2005; Renier et al., 2007).  Conditioned placed preference testing in adults has been used to 
identify zebrafish mutants with defects in cocaine (Darland and Dowling, 2001) or amphetamine 
(Webb et al., 2009) reward pathways.  The effects of both acute and chronic exposure of 
ethanol have been extensively studied in adult locomotion (Gerlai et al., 2000; Gerlai et al., 
2008), reward (Kily et al., 2008), tolerance (Dlugos and Rabin, 2003; Blaser et al., 2010; Dlugos 
et al., 2011), withdrawal (Gerlai et al., 2009; Cachat et al., 2010), aggression (Gerlai et al., 
2000), and anxiety tests (Gerlai et al., 2006; Fernandes and Gerlai, 2009; Sackerman et al., 
2010; Wong et al., 2010; Mathur and Guo, 2011; Maximino et al., 2011).  Anxiolytics, including 
nicotine (Levin et al., 2007; Bencan and Levin, 2008), buspirone, diazepam, and fluoxetine 
(Bencan et al., 2009; Maximino et al., 2011), and anxiogenics such as caffeine (Egan et al., 
2009) alter adult zebrafish anxiety-related behavioral responses as assessed by either a novel 
tank or light/dark preference paradigms.  Drugs that affect adult zebrafish learning and memory 
tests include nicotine (Levin and Chen, 2004; Levin et al., 2006), the anti-cholinergic 
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scopolamine (Kim et al., 2010; Richetti et al., 2011), the anti-histaminerigc α-
fluoromethylhistidine (Peitsaro et al., 2003), the NMDA receptor antagonist MK-801 (Swain et 
al., 2004; Blank et al., 2009), environmental neurotoxins (Smith et al., 2010), and melatonin 
(Rawashdeh et al., 2007).  Some work has also been done on the effects of neuroactive drugs 
on larval zebrafish locomotor behavior.  Ethanol and amphetamine increase locomotor activity 
at low doses but inhibit locomotion at high doses (Lockwood et al., 2004; MacPhail et al., 2009; 
Irons et al., 2010). The anti-psychotics fluphenazine, haloperidol, and clozapine cause larval 
movement defects (Giacomini et al., 2006; Boehmler et al., 2007).  Finally, several sedatives, 
including melatonin, benzodiazepines, barbiturates, histamine receptor H1 antagonists, and α-2 
adrenergic agonists also reduce larval locomotion (Zhdanova et al., 2001; Ruuskanen et al., 
2005; Renier et al., 2007). These studies collectively demonstrate the power of probing complex 
zebrafish behaviors with neuroactive small molecules. 
           
Behavioral Small Molecule Screens 
The first two large-scale screens for small molecules that modulate behavior have demonstrated 
the potential of zebrafish for psychotropic drug discovery (Kokel et al., 2010; Rihel et al., 
2010a). Rihel et al. (2010) screened the effects of nearly 4000 small molecules on zebrafish 
sleep/wake behaviors, while Kokel et al. (2010) tested how 14000 drugs altered larval 
responses to a high intensity light pulse.  Both studies leveraged the 96-well plate format to 
study behavior at high throughput and introduced the concept of clustering active compounds by 
their behavioral profiles. The quantitative, multi-dimensional behavioral profiles of each small 
molecule were used to identify unexpected relationships among molecules with similar 
behavioral outputs (Figure 1).  
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Sleep/Wake Screen 
Zebrafish larvae and adults have behavioral, pharmacological, anatomical, molecular, and 
genetic correlates of mammalian sleep (Zhdanova et al., 2001; Kaslin et al., 2004; Faraco et al., 
2006; Prober et al., 2006; Zhdanova, 2006; Yokogawa et al., 2007; Appelbaum et al., 2009; 
Rihel et al., 2010b).  First, zebrafish exhibit locomotor patterns characteristics of sleep-like 
states.  Larvae rest predominantly at night, under endogenous circadian control (Hirayama et 
al., 2005). During these rest bouts, they have increased arousal thresholds, an important 
criterion for behaviorally defined sleep-like states (Zhdanova et al., 2001; Prober et al., 2006; 
Yokogawa et al., 2007). Furthermore, zebrafish larvae exhibit rest rebound and increased 
arousal thresholds following rest deprivation, another important criterion of sleep-like states 
(Zhdanova et al., 2001; Yokogawa et al., 2007).  Second, mammalian anatomical and molecular 
aspects of sleep are conserved in zebrafish.  In particular, the zebrafish hypocretin/orexin (Hcrt) 
system, a neuropeptide regulator of sleep and arousal in mammals, is conserved (Kaslin et al., 
2004; Faraco et al., 2006; Prober et al., 2006; Yokogawa et al., 2007).  Consistent with 
mammalian studies, overexpression of Hcrt in zebrafish dramatically decreases sleep (Prober et 
al., 2006), and mutations in the Hcrt receptor lead to sleep fragmentation at night (Yokogawa et 
al., 2007). Third, small molecules that modulate rest in mammals, including melatonin, 
benzodiazepines, barbiturates, histamine receptor H1 antagonists, and α-2 adrenergic agonists 
have similar sedative effects in zebrafish larvae (Zhdanova et al., 2001; Ruuskanen et al., 2005; 
Renier et al., 2007).  Together, these studies establish zebrafish as a good model system for 
the dissection of vertebrate sleep-like states through the use of both genetics and small 
molecules. 
 
The short-term, small-scale pharmacological studies were extended by a long-term, high-
throughput screen of the sleep/wake effects of nearly 4000 small molecules (Rihel et al., 
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2010a).  Single larvae were placed into each of 80 wells of a 96-well plate, and groups of ten 
larvae were exposed to a small molecule dissolved directly in the water (and <0.3% DMSO) at 
four days post-fertilization.    Automated tracking software then monitored the long term effects 
of each compound on multiple parameters of sleep/wake behavior, including the number and 
duration of sleep bouts, the length of sleep latency (i.e. the time from lights off/on to the first rest 
bout), and the average locomotor activity during both the day and the night (Figure 1A). Rihel et 
al. screened 5648 small molecules, representing nearly 4000 unique structures known to 
modulate a variety of biological functions and molecular pathways.  Of these, more than 450 
unique structures significantly altered sleep/wake behavior compared to DMSO-treated vehicle 
controls. 
 
To help reduce the complexity of this large dataset, hierarchical clustering methods were used 
to organize the compounds by their multi-dimensional phenotypic output. These behavioral 
profiles (Figure 1A) organized compounds broadly into arousing and sedating compounds, but 
also identified compounds with selective effects on behavior. Behavioral profiles included 
increased locomotor activity only during the day or night, seizure-like responses, and effects on 
sleep latency.  Notably, compounds that shared biological targets were more likely to cluster 
together, indicating that modulation of the same molecular pathway by diverse compounds 
produced similar phenotypic outputs.  For example, selective serotonin reuptake inhibitors 
(SSRIs), including the structurally diverse 6-nitroquipazine, zimelidine, chlorpheniramine, and 
fluvoxamine, all increased total rest across the experiment.  Given that these compounds are 
structurally diverse but have the same biological target further highlights the power of the 
dataset to group compounds specifically by molecular target and phenotype and not by virtue of 
their structural similarity.  Moreover, agonists and antagonists often gave opposite phenotypic 
outcomes; for example, ß-adrenergic agonists (e.g. clenbuterol) increased waking activity while 
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ß-adrenergic antagonists (e.g. carvedilol) induced sedation.  These observations further 
validated the links forged between the modulation of specific molecular pathway targets and 
behavioral outcomes, as opposed to non-specific and off-target effects. 
 
A systematic analysis of behavior-altering compounds and their targets revealed a broad 
conservation of sleep/wake pharmacology between zebrafish and mammals and also revealed 
several modulated pathways that had been under- or unappreciated in sleep/wake biology.  
First, many modulators of neurotransmitter systems, including the noradrenaline, serotonin, 
dopamine, GABA, glutamate, histamine, adenosine, and melatonin systems, induced similar 
sleep/wake phenotypes in zebrafish as observed in mammals (Rihel et al., 2010a). Verapamil-
like L-type calcium channel inhibitors selectively increased rest with no effect on waking activity, 
ether-a-go-go related gene (ERG) potassium channel inhibitors selectively increased 
wakefulness at night, and a structural variety of anti-inflammatory compounds selectively 
increased daytime waking activity.  Finally, Rihel et al. identified structurally related 
podocarpatrien-3-ones that specifically increased rest latency.  The molecular pathway that 
these compounds modulate is currently unknown, but, given the clinical significance of sleep 
latency to insomnia (Culebras, 1996), modulation of this pathway could represent a novel 
therapeutic target for the treatment of sleep disorders.  Clinical relevance aside, the small 
molecule screen was an effective way to rapidly expand the small molecule toolkit for future 
experiments in zebrafish sleep/wake biology and identify many potentially interesting targets to 
explore. 
 
The clustering analysis not only identified small molecules that induce similar phenotypes but 
revealed that the targets of less-well characterized compounds could be predicted in a “guilt-by-
association” fashion by examining the cluster neighborhood of these poorly understood drugs.  
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The use of multi-dimensional dataset clustering to identify the targets or functional outputs of 
related compounds had been previously explored in other contexts, especially as applied to 
small molecule perturbation of gene expression (assessed by microarray).  One pioneering 
study constructed a Connectivity Map and made predictions about drug targets by using gene 
expression analysis of cell culture lines exposed to small molecule perturbagens (Lamb et al., 
2006).  Other studies have made small molecule target predictions based on other gene 
expression datasets (Mori et al., 2009), anti-malarial mechanisms of action (Plouffe et al., 2008), 
and human side effect profiles (Campillos et al., 2008).  Inspired by these studies, Rihel et al. 
used the behavioral profiles to make predictions about the targets of poorly characterized small 
molecules.  For example, the adenosine A3 antagonist, MRS-1220, co-clustered with 
monoamine oxidase (MAO) inhibitors and turned out to inhibit MAO in vitro (Rihel et al., 2010a).      
          
Photomotor Response (PMR) Screen 
Although zebrafish larvae do not exhibit robust sleep/wake behaviors until five days post 
fertilization, they do exhibit many complex responses to various stimuli as early as 24 hours 
post fertilization. Seeking a reproducible, developmentally early, and short duration embryonic 
behavior to further enhance screening throughput, Kokel and colleagues discovered that in 
response to an intense light stimulus embryonic zebrafish exhibit a stereotypical motor behavior 
called the photomotor response (PMR; Figure 1B), (Kokel et al., 2010).  During the background 
phase very few spontaneous movements are observed.  A high-intensity light pulse elicits, after 
a latency phase of about one second, a prolonged (five to seven seconds) excitation phase, 
during which the larvae move vigorously.  Following the excitation phase, larvae are refractory 
to additional light pulses for an extended time, and baseline activity is even lower than during 
the background phase.  Initial tests of select psychoactive compounds, including stimulants and 
anxiolytics, altered the PMR behavioral output. Thus, while the behavior is relatively simple, it is 
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nevertheless under the control of multiple neurotransmitter systems and suitable for neuroactive 
small molecule screening. 
 
Using an automated stage to deliver the light flash and tracking software to automatically 
observe behavioral responses in a 96-well plate format, Kokel and colleagues screened the 
effects of 14,000 small molecules on the PMR response and identified 982 unique structures 
that altered specific aspects of the PMR.  This approach identified compounds that broadly 
increased activity (e.g. the stimulant isoproterenol), broadly increased sedation (e.g. the 
anxiolytic diazepam), increased response latency (e.g. the dopamine agonist apomorphine), or 
altered the refractory period (e.g. the SSRI 6-nitroquipazine) (Kokel et al., 2010).  To organize 
this complex dataset, they further divided the PMR response into 14 behavioral parameters to 
generate a multi-dimensional profile that represents the behavioral phenotype elicited by each 
compound.  They then used hierarchical clustering to organize small molecules by profile and 
examined the behavioral associations among compounds (Figure 1B).  Importantly, the 
phenoclusters were often enriched with compounds that share mechanism of action.  For 
example, Kokel et al. identified a hyperactive phenocluster of ß-adenergic receptor agonists, a 
latency phenocluster of dopamine agonists, and a dampened excitation phenocluster enriched 
for adenosine receptor antagonists.   
 
The PMR clustergram was used to identify the molecular targets for novel compounds using the 
“guilt by association” method.  One “slow to relax” phenocluster (characterized by prolonged tail 
flexion) was enriched for known acetylcholinesterase (AchE) inhibitors but also contained 
several uncharacterized and structurally unrelated compounds (named STR-1 and STR-2; 
“slow-to relax” = STR).  Predicting that STR-1 and STR-2 were AchE inhibitors, Kokel et al. 
tested each in vitro and identified STR-1 as a bona fide structurally novel AchE inhibitor.  
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Intriguingly, STR-2 did not have AchE blocking activity in vitro, but when tested in vivo using 
larval lysates, STR-2 was a strong inhibitor.  STR-2 requires activation by an in vivo biological 
process, an important finding that highlights another advantage of in vivo, whole animal screens 
– a classical in vitro screen would likely have missed this compound.  Conversely, compounds 
with known in vitro activity can have dramatically altered or additional activities in vivo that 
cannot be predicted in advance. Taken together with the successful small molecule target 
prediction in Rihel et al. (2010a), these results suggest that behavioral profiling will be useful to 
identify previously unknown activities of small molecules. Going forward, larger studies will be 
needed to determine how reliably this approach can successfully identify targets.         
 
Conceptual and Practical Lessons 
The two small molecule behavioral screens provide the proof of principle that zebrafish screens 
can be used to uncover novel or unexpected neuroactive molecules.  However, in order for 
whole animal behavioral profiling to become a major component of psychotropic drug discovery, 
several important issues must be addressed.  As we will discuss, for some issues, these initial 
studies already hint at solutions; other issues will need to be addressed by on-going and future 
experiments.  
Dose 
All small molecule screens must deal with the issue of dose. In any sufficiently large cell-based 
or whole animal screen, compromises must be made-- there are simply too many variables in 
play that will affect the appropriate dose for any given compound. This especially involves 
questions of absorption, distribution, metabolism, excretion, and toxicity (ADMET), which can be 
different for each small molecule.  Ideally, with sufficiently high throughput (e.g. the rapid PMR 
screen), multiple doses for each compound can be tested.  For both the sleep/wake and the 
PMR screens, pilot experiments tested known psychoactive compounds across a range of 
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concentrations; typically, high doses (> 30-100 µM) were toxic while low doses (< 300 nM) 
elicited no behavioral effects (Kokel et al., 2010; Rihel et al., 2010a).  Importantly, within the 
effective concentration range, the behavioral profiles were relatively stable for most compounds, 
suggesting that similar phenotypic outputs will be identified for a range of doses.  Inevitably, 




One issue related to dose is how the zebrafish blood-brain barrier may affect the ability of the 
screening compounds to reach the zebrafish brain.  The blood-brain barrier is a protective layer 
of endothelial cells connected by tight junctions that can prevent transfer of molecules from the 
blood to the brain (Eliceiri et al., 2011). Recent evidence based on dye injections and 
expression of the tight junction proteins Zonula Occludens-1 and Claudin-1 indicates that the 
zebrafish blood-brain barrier begins to develop at 3 days post fertilization (Jeong et al., 2008; 
Xie et al., 2010; Zhang et al., 2010).  What this means for the bio-availability of small molecules 
(opposed to larger dye molecules) is unknown, especially since the circumventricular organ 
vessels lack a barrier at this age and leakage of vessels was still observed as late as 9 days 
post fertilization (Jeong et al., 2008; Xie et al., 2010).  The initial behavioral screens were able 
to identify psychotropic compounds even at five to seven days post fertilization, indicating their 
ability to reach molecular targets within the larval zebrafish brain, but it is unknown what fraction 
of small compounds does not reach the brain. 
 
Poly-pharmacology   
One challenge to the discovery of novel neuroactive compounds for the treatment of CNS 
disorders is poly-pharmacology.  Psychotropic drugs often affect multiple targets, and this broad 
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pharmacological activity may underlie the efficacy of many CNS drugs (Agid et al., 2007; 
Hopkins, 2008).  The nature of single-target, in vitro screens makes it impossible to identify 
therapeutic compounds whose mechanism of action requires activity on multiple biological 
pathways.  Whole animal behavioral screens, however, can uncover these promiscuous small 
molecules because the endpoint is a behavioral output that is dependent on the network 
interaction of multiple pathways.  For example, in the sleep/wake screen, compounds with 
inhibitory activity on both dopamine reuptake and muscarinic acetylcholine receptors generated 
behavioral profiles distinct from small molecules that inhibited only one of these targets (Rihel et 
al., 2010a). Thus, anomalous phenoclusters within the behavioral dataset may motivate a 
deeper investigation of potential poly-pharmacological effects.  
 
Mapping of Small Molecules to Zebrafish Receptors    
The interpretation of zebrafish small molecule assays often rests on the assumption that the 
annotated activity of a small molecule, which is usually based on mammalian receptor data, will 
accurately reflect the activity on the zebrafish target.  This need not be the case, however, as 
there can be dramatic inter-species activity differences, even among mammals.  For example, 
the pharmacological profile of histamine receptors varies so widely between species that some 
compounds (e.g. FUB-322) are agonists on human histamine H3 receptors and inverse agonists 
on the rat receptor (Lovenberg et al., 2000; Seifert et al., 2003; Esbenshade et al., 2007).   
Discrepancies between zebrafish and mammalian receptor pharmacology could account for 
disparities in observed sleep/wake phenotypes in the small molecule screen. For example, 
dopamine D1 receptor agonists give opposite phenotypes in larval fish (sedation) and mammals 
(arousal) (Ongini et al., 1987; Bo et al., 1988; Trampus et al., 1993; Rihel et al., 2010a).  It 
remains an open question whether this difference is due to altered activity of molecules on 
dopamine receptors or other differences in zebrafish dopamine system biology.  The situation is 
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further complicated because of differences between the number of neurotransmitter receptor 
subtypes between humans and zebrafish.  To take one example, there are five dopamine 
receptors in mammals, while there are eight in zebrafish (Panula et al., 2010). How small 
molecule activity maps to each of the zebrafish receptors in most cases is unknown.        
 
Both the sleep/wake and the PMR screen partially mitigate the zebrafish annotation problem.  
First, confidence in the appropriate molecular interpretation is bolstered when multiple 
structurally diverse compounds give the same phenotype, especially when the small molecules 
target different components of the same signaling pathway.  Second, the presence of 
agonist/antagonist pairs that yield opposite phenotypes is encouraging.  Nevertheless, the 
systematic analysis of the binding activities of small molecules on zebrafish receptor subtypes 
will be needed to enhance the quality of drug library annotation for zebrafish small molecule 
screens.  Such efforts include recent in vitro analyses that show conserved pharmacology of 
zebrafish opioid receptors (Gonzalez-Nunez et al., 2007; de Velasco et al., 2009), the nociceptin 
receptor (Rivas-Boyero et al., 2011), the zebrafish M2 muscarinic receptor (Hsieh and Liao, 
2002), melanocortin receptors (Ringholm et al., 2002), the androgen receptor (Hossain et al., 
2008) and bradykinnin receptors (Duner et al., 2002; Bromee et al., 2005). Radiolabel-binding 
studies of small molecule agonists/antagonists in zebrafish brain membranes or slices are also 
useful, especially when coupled with competitive binding assays, as shown in studies on 
muscarinic acetylcholine receptors (Williams and Messer, 2004), GABA-A and GABA-B 
receptors (Renier et al., 2007), H2 and H3 histamine receptors (Peitsaro et al., 2000; Peitsaro et 
al., 2007), and adrenergic receptors (Ruuskanen et al., 2005).  While these studies paint an 
overall picture of conservation between zebrafish and mammalian neural signaling systems, 
more detailed characterization will greatly assist the proper interpretation of small molecule 
behavioral screening efforts. 
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Expansion of the Behavioral Assays 
In principle, as long as a behavior is modulated by multiple major neuronal signaling systems, 
that behavior can be used to discover novel psychotropic compounds.  However, this approach 
effectively limits the scope of the neuroactive screen to only those molecular signaling pathways 
involved in the screened behavior, leaving potentially important systems unexplored.  One way 
to combat this issue is to systematically increase the behavioral search space and expand the 
multidimensional behavioral profile to include many more behavioral parameters.  There is an 
ever-expanding list of larval zebrafish behaviors that are amenable to high-throughput screens 
and that can be included as part of an automated behavioral screening repertoire (Kokel and 
Peterson, 2008; Mathur and Guo, 2010; Tierney, 2011).  These include a range of visual 
behaviors such as eye saccade responses to a rotating drum (the optokinetic reflex, or OKR) 
(Brockerhoff et al., 1995), motor responses to a moving grating (optomotor response, or OMR) 
(Neuhauss et al., 1999), or locomotor responses to changes in light intensity (the visual-motor 
response, VMR) (Emran et al., 2007; Emran et al., 2010).  Zebrafish larvae also have complex 
behavioral startle responses to acoustic stimuli (Burgess and Granato, 2007), and these 
responses habituate over time as a form of non-associative learning (Best et al., 2008). 
Additionally, the zebrafish startle response to a high intensity stimulus can be inhibited by a 
lower intensity pulse (pre-pulse inhibition, PPI) (Burgess and Granato, 2007).  Since change in 
PPI is an endophenotype associated with human schizophrenia (Braff et al., 2001), the 
zebrafish acoustic startle and PPI phenotypes are an exciting assay for further study and have 
already yielded a PPI impaired mutant, Ophelia (Burgess and Granato, 2007).  Larval zebrafish 
also exhibit locomotor responses to changes in temperature and noxious chemicals (Prober et 
al., 2008).  Finally, assays to study more integrated behaviors, such as prey capture, are also 
established in zebrafish larvae (Budick and O'Malley, 2000; Borla et al., 2002; Gahtan et al., 
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2005).  Combining several of these behavioral responses together into a single assay to 
generate a larger behavioral profile will be an attractive way to increase the resolving power and 
the search space of neuroactive screens.                           
 
Clinical Relevance of  Behavioral Assays 
Although direct human clinical relevance is not essential for fruitful neuroactive screening, 
disease-relevant behavioral models are also important, especially to identify the most promising 
candidate molecules for mammalian follow-up studies.  No animal model can perfectly 
recapitulate complex human psychiatric and CNS diseases, but the closer an animal model can 
mimic critical aspects of disease, the more likely the search for disease-ameliorating small 
molecules will be successful.  One way to create more disease relevant zebrafish models is to 
identify small molecule pre-treatments that recapitulate important clinical aspects of disease.  
For example, the sleep/wake screen found that MK-801 and other NMDA receptor antagonists 
used in drug-induced schizophrenia animal models (Olney et al., 1999) similarly increased 
locomotor behavior (Adriani et al., 1998; Rihel et al., 2010a), a result confirmed in other adult 
and larval zebrafish experiments (Swain et al., 2004; Chen et al., 2010; Seibt et al., 2010). The 
PMR screen identified paralysis in zebrafish treated with organophosphates (Kokel et al., 2010), 
a phenotype that was reversed by antidotes used to treat human organophosphate toxicity 
(Bajgar, 2004).  Pentylenetetrazole (PTZ) treatment, which causes seizures in zebrafish larvae 
(Baraban et al., 2005), was used to identify potential seizure resistance genes (Baraban et al., 
2007) and would be amenable to small molecule screens for novel anti-convulsants.  Other 
drug-induced larval phenotypes with promising clinical relevance include ethanol intoxication 
(Lockwood et al., 2004; MacPhail et al., 2009), nicotine dependence (Petzold et al., 2009), and 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced ablation of dopamine neurons as 
a model for Parkinson’s disease (Bretaud et al., 2004; Lam et al., 2005; McKinley et al., 2005; 
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Thirumalai and Cline, 2008).  Finally, zebrafish mutant models of human psychiatric diseases 
can serve as chemical screening start points.  The development of relevant zebrafish behavioral 
and CNS mutants is still in its infancy but rapidly expanding to include neurodegenerative 
disorders, autism, schizophrenia, and Huntington’s disease (see recent reviews by Best and 
Alderton, 2008; Kabashi et al., 2010; Mathur and Guo, 2010; Tierney, 2011).  Small molecule 
suppressor/enhancer screens on the relevant mutant backgrounds will be a rapid way to identify 
molecular pathways that interact with disease genes.               
 
Conclusions 
Small molecule behavioral screening can now be performed with sufficient throughput to be 
useful in the discovery of neuroactive compounds.  Where might such zebrafish screens fit in 
the neuroactive drug pipeline?  They could be used as a testing ground for previously curated 
small molecule leads at a stage before more expensive testing is performed in rodents.  For 
example, much effort has recently been put into the identification of potent hypocretin receptor 
antagonists such as almorexant (Brisbare-Roch et al., 2007; Neubauer, 2010).  Screening 
candidate compounds in zebrafish behavioral models of hypocretin-induced hyperactivity 
(Prober et al., 2006) could serve as a cheap way to identify the most promising non-toxic 
molecules with good in vivo pharmacological activity before testing in mammals.  As even 
higher throughput is achieved, zebrafish screens could also serve as a primary and early 
screening stage for novel neuroactives that would then be further optimized for increased 
potency by medicinal chemists.  By testing a larger and more diverse set of chemical structures 
with unknown pharmacological properties, zebrafish behavioral assays could identify wholly 
novel neuroactive compounds.  Unlike in vitro assays designed around single targets, these 
newly identified compounds would already be shown to have promising in vivo properties.       
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Finally, one should not ignore another powerful use of the small molecule screening paradigm—
to gain novel insights in the mechanistic underpinnings of behavior.  Using well annotated 
chemical libraries, these molecules become tools to rapidly test the functional importance of 
many neuro-modulatory pathways in specific behaviors.  Once critical neural signaling events 
have been implicated as modulators of behavior by pathway agonists and antagonists, more 
targeted experiments can be designed to more deeply test how the pathway modulates 
behavior and where in the brain that modulation takes place.  Thus, the small molecule screens 
provide a bridge between molecular targets and behavioral outputs.  A future challenge will be 
to carefully dissect the underlying neuronal circuits that underpin this behavioral control. 
 
Figure 1.  Converting Quantitative Behavioral Data into Behavioral Profiles for Clustering.  A) In 
the sleep/wake screen, larval activity data is collected over several days (left).  The data for 
each small molecule gets broken into multiple parameters and converted into a behavioral 
profile for hierarchical clustering (right).  The clustering organizes the drugs (rows) based on 
phenotype.  In this example, the top three drugs cluster because they increase average sleep 
bout lengths.  The lower cluster contains three drugs that increase daytime waking activity.  B) 
In the PMR screen, 30 seconds of larval activity data in response to an intense light pulse is 
collected (left).  This data is also converted into behavioral profiles and clustered based on 
phenotype (right).  In the top cluster, three drugs increase activity during the refractory period, 
whereas in the lower cluster, three drugs shorten the latency period. Modified from Rihel et al., 
(2010) and Kokel et al., (2010). 
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